Everything below concerns liquid chromatography. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-19. Numbers and descriptions here follow the published literature rather than marketing material.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its cysteine residue carries a thiol group, which allows the molecule to participate in reduction and oxidation reactions. The compound exists in most living cells, where the reduced form, often abbreviated GSH, is usually more abundant than the oxidized disulfide form, GSSG. Intracellular concentrations are commonly in the millimolar range, while extracellular concentrations are much lower. This uneven distribution supports its role as a major cellular redox buffer.
Cells synthesize glutathione through two ATP-dependent enzymatic steps. The first step combines glutamate and cysteine to form gamma-glutamylcysteine, catalyzed by glutamate-cysteine ligase. The second step adds glycine, producing the complete tripeptide, catalyzed by glutathione synthetase. Glutathione itself can inhibit the first enzyme, providing negative feedback when levels are high. Because cysteine is often limiting, its availability influences how quickly the pathway proceeds. These reactions occur in the cytosol, and the resulting glutathione can be distributed to other compartments.
Glutathione functions in redox balance, detoxification, and sulfur amino acid storage. It participates in reactions that help maintain ascorbate and protein thiol status. The molecule serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. These enzymes reduce peroxides and conjugate electrophiles, respectively. Glutathione also contributes to the metabolism of xenobiotics and to the transport of cysteine between tissues. How interorgan transport and tissue-specific regulation shape whole-body pools remains an active area of study.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
For solid glutathione reagents, storage at low temperature and protection from moisture and light are typical precautions. Aqueous solutions can oxidize over time, and pH affects stability; alkaline conditions generally promote thiol oxidation. Some protocols prepare fresh solutions, while others use antioxidants or chelators to limit metal-catalyzed oxidation. Purity and counterion content can vary among commercial preparations, affecting concentration calculations. Certificates of analysis and validated assays help verify identity and purity.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Reduced glutathione (GSH) |
| Molar mass | 307.32 g/mol | Calculated for C10H17N3O6S |
| Appearance | White to off-white powder | Typical solid form |
| Solubility | Water-soluble | Polar tripeptide |
| Common synonyms | GSH; L-glutathione | Gamma-glutamylcysteinylglycine |
Interpreting glutathione measurements requires attention to pre-analytical variables. The GSSG concentration in a sample can rise artificially during storage or processing, making the GSH/GSSG ratio unreliable if not controlled. Reference ranges vary by specimen type, assay, and population, so comparisons across studies are difficult. Plasma glutathione is low and sensitive to hemolysis, while whole blood reflects primarily erythrocyte content. Many studies measure total glutathione rather than the reduced and oxidized forms separately, which limits conclusions about redox status.
Accurate measurement of glutathione begins with careful sample handling. Because GSH oxidizes rapidly to GSSG, samples must be processed quickly or frozen immediately. Acid precipitation with metaphosphoric acid or perchloric acid is common; it lowers pH, precipitates proteins, and helps preserve the reduced form. Chelating agents such as EDTA can limit metal-catalyzed oxidation. For whole blood, hemolysis releases glutathione from erythrocytes, so plasma and serum values differ substantially from whole blood values.
Several analytical methods can quantify glutathione, including high-performance liquid chromatography (HPLC) with UV or fluorescence detection for separating GSH and GSSG. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers higher specificity and sensitivity, often detecting nanomolar concentrations. The enzymatic recycling assay, often called the Tietze method, measures total glutathione by coupling reduction of GSSG to a colorimetric or fluorometric readout. Capillary electrophoresis and electrochemical detection are also used in specialized laboratories. Each method has distinct advantages and limitations regarding throughput, cost, and susceptibility to interference.
Quality control for glutathione measurements includes calibration with authenticated standards, internal standards where available, blank correction, and spike recovery checks. Because glutathione can form during sample processing or degrade before analysis, pre-analytical handling is a major source of variability. Interlaboratory comparisons often show differences in reported values due to method-specific calibration and detection principles. Interpretive thresholds are context-dependent, and no single reference range applies across all tissues or matrices. Researchers generally report both reduced and oxidized forms, along with the method and sample handling details.
Quantification of glutathione in biological or food samples commonly uses liquid chromatography coupled to ultraviolet, fluorescence, electrochemical, or mass spectrometric detection. Because the thiol group oxidizes readily, samples are often acidified or derivatized immediately after collection to stabilize reduced glutathione. Enzymatic recycling assays and colorimetric kits offer higher throughput but generally lower specificity than chromatographic methods. Mass spectrometry can distinguish glutathione from related thiols and allow simultaneous measurement of oxidized forms. Reported concentrations depend strongly on sample type, extraction procedure, and analytical platform.
γ-Aminobutyric acid (GABA) prodrugs include progabide and tolgabide. Picamilon (N-nicotinoyl-GABA) has been claimed to be a prodrug of GABA, but has not actually been demonstrated to be converted into GABA. N-Benzoyl-GABA is of very similar chemical structure as picamilon and has also been claimed to be a prodrug of GABA, but this remains unclear similarly. Pivagabine (N-pivaloyl-GABA) was once thought to be a prodrug of GABA, but this proved not to be the case. Cetyl-GABA (GABA cetyl ester) is another prodrug of GABA. 4-Amino-1-butanol is known to be converted into GABA through the actions of aldehyde reductase (ALR) and aldehyde dehydrogenase (ALDH). 4-Amino-1-butanol is to GABA as 1,4-butanediol (4-hydroxy-1-butanol; 1,4-BD) is to γ-hydroxybutyric acid (GHB) (with 1,4-BD being a well-known prodrug of GHB). The metabolic intermediate γ-aminobutyraldehyde (GABAL) is also converted into GABA. A number of γ-hydroxybutyric acid (GHB) prodrugs are known. These include 1,4-butanediol (1,4-BD) and γ-butyrolactone (GBL), as well as the metabolic intermediate γ-hydroxybutyraldehyde (GHBAL).
The museum is located in a small two-storey building where laboratory of physics (on the first floor) and chemical laboratory (on the second floor) was designed. It was the first chemical laboratory of Kazan University. The first professor was N.N. Zinin, who studied abroad and learned new method of teaching chemistry and began to apply it in Kazan University. This method combined practical and lecture classes that is still familiar to students. There are no usual stalls and stands in the museum. It is a memorial laboratory of the 19th century which includes Butlerov's lecture room, a library, the laboratory itself, a hall for exhibiting chemical preparations and laboratory equipment of 19–20th centuries, and the study of the head of the laboratory (Butlerov's study). Nowadays in the main hall of the museum lectures and seminars and defence of master's and doctoral theses are conducted. In the side rooms you may observe modern laboratories.
RNA polymerase III performs "intrinsic-like" termination. The majority of genes transcribed by RNAP III have a poly(dT) region. However, although poly(dT) pauses every RNA polymerase, it alone cannot be insufficient; some other mechanism must destabilize the clamp. In RNAP III, some poly(dT) sites are indeed occasionally read-through: some genes have multiple such regions, allowing transcripts of different lengths to be produced. The instability of rU:dA hybrids likely is essential to termination by RNAP III. Parts of core subunits C1 and C2, as well as "subcomplexes" C53/37 and C11 are functionally important. A number of extraneous factors can modify the termination behavior. Rho factor WebGeSTer Trp operon
All mammalian alkaline phosphatase isoenzymes except placental (PALP and SEAP) are inhibited by homoarginine, and, in similar manner, all except the intestinal and placental ones are blocked by levamisole. Phosphate is another inhibitor which competitively inhibits alkaline phosphatase. Another known example of an alkaline phosphatase inhibitor is [(4-Nitrophenyl)methyl]phosphonic acid. In metal contaminated soil, alkaline phosphatase are inhibited by Cd (Cadmium). In addition, temperature enhances the inhibition of Cd on the enzyme activity, which is shown in the increasing values of Km. In humans, alkaline phosphatase is present in all tissues throughout the body, but is particularly concentrated in the liver, bile duct, kidney, bone, intestinal mucosa and placenta. In the serum, two types of alkaline phosphatase isozymes predominate: skeletal and liver. During childhood the majority of alkaline phosphatase are of skeletal origin. Humans and most other mammals contain the following alkaline phosphatase isozymes:
Sources: en.wikipedia.org
Tranexamic acid is sometimes used to treat heavy menstrual bleeding. When taken by mouth it both safely and effectively treats regularly occurring heavy menstrual bleeding and improves quality of life. Another study demonstrated that the dose does not need to be adjusted in females who are between ages 12 and 16. In a 10-year study, tranexamic acid and other oral medicines (mefenamic acid) were found to be as effective as the levonorgestrel intrauterine coil; the same proportion of women had not had surgery for heavy bleeding and had similar improvements in their quality of life. Tranexamic acid is sometimes used (often in conjunction with oxytocin) to reduce bleeding after childbirth. Death due to postpartum bleeding is reduced in women receiving tranexamic acid.
Vaginal gels are forms of medication that are water-based. They are applied using a plastic applicator to distribute the gel throughout the length of the vaginal canal. These gels tend to have release kinetics that are fast acting, which makes them useful for treatment of irritations. Antibiotics are often distributed in the form of a gel for treatment of common infections, including sexually transmitted infections (STIs). The gels also have the benefit of being lubricating, which grants additional relief to symptoms of dryness and itching that is common with vaginal infections. Gels that are in the form of liposomal structure have been shown to retain substances for extensive periods of time, making them useful for slow release of drugs administered through the cervical drug delivery route
Autosomal-dominant mutations in APP cause hereditary early-onset Alzheimer's disease (familial AD, fAD). This form of AD accounts for no more than 10% of all cases, and the vast majority of AD is not accompanied by such mutations. However, familial Alzheimer's disease is likely to result from altered proteolytic processing. This is evidenced by the fact that many mutations that lead to fAD occur near γ-secretase cleavage sites on APP. One of the most common mutations causing fAD, London Mutation, occurs at codon 717 of the APP gene, and results in a valine to isoleucine amino acid substitution. Histochemical analysis of the APP V717I mutation has revealed extensive Aβ pathology throughout neuroaxis as well as widespread cerebral amyloid angiopathy (CAA). The gene for the amyloid precursor protein is located on chromosome 21, and accordingly people with Down syndrome have a very high incidence of Alzheimer's disease.
Tranexamic acid can be used in skincare products as a cosmetic active to reduce the appearance of inflammation and hyperpigmentation. Tranexamic acid is a zwitterion amino acid, and has a low permeability coefficient in the stratum corneum. Tranexamic acid can be combined with penetration enhancers and microneedling to overcome this limitation. Cosmetic uses may also employ lipophilic derivatives of tranexamic acid (ester prodrugs like Cetyl tranexamate mesylate) that are not zwitterionic and thus have improved skin permeability. Allergic to tranexamic acid History of seizures History of venous or arterial thromboembolism or active thromboembolic disease Severe kidney impairment due to accumulation of the medication, dose adjustment is required in mild or moderate kidney impairment
These drugs have been derived from NSAIDs. The cyclooxygenase enzyme inhibited by NSAIDs was discovered to have at least two different versions: COX-1 and COX-2. Research suggested most of the adverse effects of NSAdiated by blocking the COX-1 (constitutive) enzyme, with the analgesic effects being mediated by the COX-2 (inducible) enzyme. Thus, the COX-2 inhibitors were developed to inhibit only the COX-2 enzyme (traditional NSAIDs block both versions in general). These drugs (e.g., rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular. After widespread adoption of the COX-2 inhibitors, it was discovered that most of the drugs in this class increase the risk of cardiovascular events by 40% on average. This led to the withdrawal of rofecoxib and valdecoxib, and warnings on others. Etoricoxib seems relatively safe, with the risk of thrombotic events similar to that of non-coxib NSAID diclofenac.
Sources: en.wikipedia.org
The first symptom of CJD is usually rapidly progressive dementia, leading to memory loss, personality changes, and hallucinations. Myoclonus (jerky movements) typically occurs in 90% of cases, but may be absent at initial onset. Other frequently occurring features include anxiety, depression, paranoia, obsessive-compulsive symptoms, and psychosis. This is accompanied by physical problems such as speech impairment, balance and coordination dysfunction (ataxia), changes in gait, and rigid posture. In most people with CJD, these symptoms are accompanied by involuntary movements. Rarely, unusual symptoms like the alien limb phenomenon have been observed. The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks. Most affected people die six months after initial symptoms appear, often of pneumonia due to impaired coughing reflexes. About 15% of people with CJD survive for two or more years. The symptoms of CJD are caused by the progressive death of the brain's nerve cells, which are associated with the build-up of abnormal prion proteins forming in the brain. When brain tissue from a person with CJD is examined under a microscope, many tiny holes can be seen where the nerve cells have died. Parts of the brain may resemble a sponge where the prions were infecting the areas of the brain.
Camurus is a company focused on the development of lipid lyotropic liquid crystal structures for pharmaceutical drug delivery applications. These structures are well-defined three-dimensional formations consisting of lipophilic and hydrophilic domains that can be either interconnected or isolated depending on the environmentally induced phase conditions. The unique crystalline structures offer a unique way of encapsulating and transporting Active pharmaceutical ingredients, such as small molecules, peptides and proteins through the body. The structures also allow for the use of controlled release and prevention of degradation of fragile short half live molecules, a serious issue for amino-acid based drugs.
(CH3)2CO → CH3 + CH3CO The latter process is relevant to the atmospheric chemistry of acetone. Acetone can then be metabolized either by CYP2E1 via methylglyoxal to D-lactate and pyruvate, and ultimately glucose/energy, or by a different pathway via propylene glycol to pyruvate, lactate, acetate (usable for energy) and propionaldehyde. About a third of the world's acetone is used as a solvent, and a quarter is consumed as acetone cyanohydrin, a precursor to methyl methacrylate. Acetone is used to synthesize methyl methacrylate. It begins with the initial conversion of acetone to acetone cyanohydrin via reaction with hydrogen cyanide (HCN): (CH3)2CO + HCN → (CH3)2C(OH)CN In a subsequent step, the nitrile is hydrolyzed to the unsaturated amide, which is esterified: (CH3)2C(OH)CN + CH3OH → CH2C(CH3)CO2CH3 + NH3 The third major use of acetone (about 20%) is synthesizing bisphenol A. Bisphenol A is a component of many polymers such as polycarbonates, polyurethanes, and epoxy resins. The synthesis involves the condensation of acetone with phenol:
The protein is 82.3 kDa and has a 40 amino acid long LEM domain located at its amino-terminal region. In its carboxyl end it has a RNA recognition motif (RRM). The LEM domain is also common to two other integral proteins of the INM: lamina-associated polypeptide 2 (LAP2) and emerin. The LEM segment enables LEMD3 to attach to the barrier-to-autointegration factor (BAF), and therefore, indirectly interact with the chromatin. LEMD3 also has several implications in regulating the cytokine family such as the transforming growth factor beta (TGF-β) and bone morphogenic protein (BMPs). The RRM domain in its carboxylic region attaches to the SMAD (protein) proteins, which is involved in mediating TGF-β cellular signalling. Consequently, LEMD3 indirectly regulates downstream genes. LEMD3 seems to play an important role in regulating the expression of several fundamental genes. LEMD3 has been associated with laminopathies as well as osteopoikilosis. Mutations in the LEMD3 gene have been linked to several genetic diseases such as osteopoikilosis, melorheostosis and Buschke–Ollendorff syndrome.
The composition and rate of CSF generation are influenced by hormones and the content and pressure of blood and CSF. For example, when CSF pressure is higher, there is less of a pressure difference between the capillary blood in choroid plexuses and CSF, decreasing the rate at which fluids move into the choroid plexus and CSF generation. The autonomic nervous system influences choroid plexus CSF secretion, with activation of the sympathetic nervous system decreasing secretion and the parasympathetic nervous system increasing it. Changes in the pH of the blood can affect the activity of carbonic anhydrase, and some drugs (such as furosemide, acting on the Na-K-Cl cotransporter) have the potential to impact membrane channels.
Sources: en.wikipedia.org
Glutathione is built from three amino acids: glutamate, cysteine, and glycine. The linkage involves the gamma-carboxyl group of glutamate rather than the alpha-carboxyl group, which is unusual for peptides. This structure protects the bond from some common peptidases.
It is present in nearly all cells, with notable amounts in the liver, kidneys, and red blood cells. The highest intracellular concentrations are usually in the millimolar range. Levels differ by tissue, age, and physiological state.
It is not classified as an essential nutrient because cells can synthesize it from amino acids. Dietary sources exist, but their contribution to tissue pools is not fully established. The body's production depends on enzyme activity and precursor availability.
Preanalytical factors such as sample type, time to processing, and stabilization method can change GSH and GSSG amounts. Analytical method and calibration also contribute to variation. Comparing absolute values across studies requires caution.